Strokectomy in Malignant Cerebral Media Infarction
Launched by UNIVERSITY OF ROSTOCK · Jul 2, 2024
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new surgical procedure called strokectomy for patients who have experienced a severe type of stroke known as malignant middle cerebral artery (MCA) infarction. Currently, the standard treatment is a surgery called decompressive hemicraniectomy, which helps relieve pressure in the brain. However, researchers believe that removing the damaged brain tissue itself may help improve outcomes for some patients. The study aims to see if this new approach is safe and effective for patients who have suffered a significant stroke.
To participate in this trial, individuals must be at least 18 years old and have experienced a stroke affecting a large part of the MCA area within the past 48 hours. They should also be able to respond to stimuli, as those with very severe brain injury or other serious conditions may not be eligible. Participants will receive the new surgical treatment, and the study will closely monitor their recovery. This trial is currently recruiting participants, and it offers hope for improving care for those affected by severe strokes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older
- • Ischemic middle cerebral artery (MCA) infarction at least two thirds of the MCA territory
- • Clinical symptoms of acute unilateral MCA infarction less than 48 hours prior to the initiation of treatment
- Exclusion Criteria:
- • Preexisting modified Rankin Scale \>2
- • Absence of pupillary reflexes or GCS \<6
- • Intracerebral hemorrhage or other associated brain lesions
- • Contraindications for surgery
- • Estimated life expectancy of less than 3 years
About University Of Rostock
The University of Rostock is a prestigious academic institution located in Germany, dedicated to advancing medical research and education. With a strong emphasis on interdisciplinary collaboration, the university is committed to conducting innovative clinical trials that address pressing health challenges. Its research initiatives are supported by state-of-the-art facilities and a team of experienced professionals, enabling the exploration of cutting-edge therapies and interventions. The University of Rostock aims to contribute to the scientific community and improve patient outcomes through rigorous clinical investigation and the dissemination of knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rostock, Mecklenburg Vorpommern, Germany
Patients applied
Trial Officials
Sae-Yeon Won, MD
Principal Investigator
Neurosurgery, University Medical Center Rostock
Florian Gessler, MD PhD
Study Director
Neurosurgery, University Medical Center Rostock
Matthias Wittstock, MD
Study Chair
Neurology, University Medical Center Rostock
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported